Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25523481 | 0.78 | ALDH1A1 (0.49) | ALDH1A1HTR2CDDB1CRBN | |
| SCHEMBL25557239 | 0.76 | OPRM1 (0.50) | ALDH1A1DDB1CRBN | |
| SCHEMBL21828678 | 0.76 | CYP3A4 (0.51) | ALDH1A1 | |
| SCHEMBL21828677 | 0.76 | CYP3A4 (0.51) | ALDH1A1 | |
| SCHEMBL19625794 | 0.75 | HPGD (0.55) | ALDH1A1HTR2C | |
| SCHEMBL25879050 | 0.74 | OPRM1 (0.45) | ALDH1A1DDB1CRBN | |
| SCHEMBL19013539 | 0.73 | ALDH1A1 (0.53) | ALDH1A1 | |
| SCHEMBL25089937 | 0.72 | ALDH1A1 (0.49) | ALDH1A1HTR2CGLRA1 | |
| SCHEMBL9965984 | 0.72 | FABP7 (0.52) | ALDH1A1HTR2C | |
| SCHEMBL25707989 | 0.72 | ALDH1A1 (0.49) | ALDH1A1HTR2CDDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | ALDH1A1 1110/4885HTR2C 900/4885DDB1 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.